The Senescence-Like Activity of BMS-470539 Is Associated With Anti-Fibrotic Actions in Models of Dermal Fibrosis

The study explores the use of the melanocortin compound BMS-470539 to target fibrosis by inducing a 'senescence-like' state in human dermal fibroblasts, particularly from systemic sclerosis patients. This state is characterized by proliferation arrest and reduced pro-inflammatory activity, leading to the downregulation of fibrosis markers. In vitro and in vivo models, including a bleomycin-induced skin fibrosis murine model, demonstrated that BMS-470539 effectively reduced skin thickness and fibrosis markers without causing additional fibrosis when administered intradermally. The findings suggest a promising therapeutic strategy to manage fibrosis and potentially other diseases with shared pathogenic mechanisms, such as arthritis.